Human interleukin-4 possesses two distinct sites for receptor activation. A signalling site, comprising residues near the C-terminus on helix D, determines the efficacy of interleukin-4 signal transduction without affecting the binding to the interleukin-4 receptor a subunit. A complete antagonist and a series of low-efficacy agonist variants of human interleukin-4 could be generated by introducing combinations of two or three negatively charged aspartic acid residues in this site at positions 121, 124, and 125. One of the double variants, designated [R121D,Y124D]interleukin-4, with replacements of both Argl21 and Tyrl24 by aspartic acid residues was completely inactive in all analysed cellular responses. The loss of efficacy in [R121D,Y 124Dlinterleukin-4 is estimated to be larger than 2000-fold. Variant [R121D,Y124D]interleukin-4 was also a perfect antagonist for inhibition of interleukin-13-dependent responses in B-cells and the TF-1 cell line with a K, value of approximately 100 pM. In addition, inhibition of both interleukin-4-induced and interleulun-13-induced responses could be obtained by monoclonal antibody X2/45 raised against interleukin-4Re,, the extracellular domain of the interleukin-4 receptor a subunit. These results indicate that efficient interleukin-4 antagonists can be designed on the basis of a sequential two-step activation model. In addition, the experiments indicate the functional participation of the interleukin-4 receptor a subunit in the interleukin-13 receptor system.Human interleukin-4 (IL-4) activates its cognate receptor system by sequential binding to two different receptor subunits. The first high-affinity binding step (& 100 pM) involves the interaction between IL-4 receptor a subunit (Beckmann et al., 1992;Galizzi et al., 1990;Idzerda et al., 1990) and IL-4 amino acid residues located on helices A and C (Kruse et al., 1993;Ramanathan et al., 1993). The subsequent second binding step involves a signalling site on helix D of IL-4 (Kruse et al., 1992) and a further receptor subunit, which according to recent evidence (Kondo et al., 1993;Russell et al., 1993) is probably the y chain of the IL-2 receptor system, now designated yc.Such a sequential two-step binding mechanism leading to receptor activation suggests a rationale for the design of antagonistic cytokine variants (Cunningham et al., 1991 ;De Vos et al., 1992). If the first high-affinity binding site is retained and the second signalling site is either destroyed by (Fuh et al., 1992;Kruse et al., 1992) or blocked by monoclonal antibodies (Reusch et al., 1994), the oligomerisation process stops at the level of the unproductive 1 : 1 complex between the cytokine and the first receptor subunit. The signalling site of human IL-4 comprises side chains of Argl21, Tyrl24 and Ser125. Previous results have shown that variants [R121D]IL-4 and [S225D]IL-4 have approximately 30% partial agonist activity and variant [Y124D]IL-4 has less than 1 % partial agonist activity for T-cell proliferation compared to wild-type IL-4. High-affinit...